QQQ   431.12 (-1.63%)
AAPL   173.31 (-1.84%)
MSFT   414.21 (-1.82%)
META   499.41 (-2.44%)
GOOGL   155.02 (-1.72%)
AMZN   183.93 (-1.18%)
TSLA   162.52 (-4.99%)
NVDA   867.05 (-1.68%)
AMD   160.98 (-1.41%)
NIO   3.85 (-6.33%)
BABA   70.32 (-1.36%)
T   16.17 (-0.86%)
F   12.23 (-3.01%)
MU   121.27 (-1.02%)
GE   153.36 (-0.82%)
CGC   6.89 (-11.67%)
DIS   113.06 (-0.83%)
AMC   2.51 (-5.28%)
PFE   25.85 (-0.04%)
PYPL   63.42 (-1.81%)
XOM   119.83 (-0.45%)
QQQ   431.12 (-1.63%)
AAPL   173.31 (-1.84%)
MSFT   414.21 (-1.82%)
META   499.41 (-2.44%)
GOOGL   155.02 (-1.72%)
AMZN   183.93 (-1.18%)
TSLA   162.52 (-4.99%)
NVDA   867.05 (-1.68%)
AMD   160.98 (-1.41%)
NIO   3.85 (-6.33%)
BABA   70.32 (-1.36%)
T   16.17 (-0.86%)
F   12.23 (-3.01%)
MU   121.27 (-1.02%)
GE   153.36 (-0.82%)
CGC   6.89 (-11.67%)
DIS   113.06 (-0.83%)
AMC   2.51 (-5.28%)
PFE   25.85 (-0.04%)
PYPL   63.42 (-1.81%)
XOM   119.83 (-0.45%)
QQQ   431.12 (-1.63%)
AAPL   173.31 (-1.84%)
MSFT   414.21 (-1.82%)
META   499.41 (-2.44%)
GOOGL   155.02 (-1.72%)
AMZN   183.93 (-1.18%)
TSLA   162.52 (-4.99%)
NVDA   867.05 (-1.68%)
AMD   160.98 (-1.41%)
NIO   3.85 (-6.33%)
BABA   70.32 (-1.36%)
T   16.17 (-0.86%)
F   12.23 (-3.01%)
MU   121.27 (-1.02%)
GE   153.36 (-0.82%)
CGC   6.89 (-11.67%)
DIS   113.06 (-0.83%)
AMC   2.51 (-5.28%)
PFE   25.85 (-0.04%)
PYPL   63.42 (-1.81%)
XOM   119.83 (-0.45%)
QQQ   431.12 (-1.63%)
AAPL   173.31 (-1.84%)
MSFT   414.21 (-1.82%)
META   499.41 (-2.44%)
GOOGL   155.02 (-1.72%)
AMZN   183.93 (-1.18%)
TSLA   162.52 (-4.99%)
NVDA   867.05 (-1.68%)
AMD   160.98 (-1.41%)
NIO   3.85 (-6.33%)
BABA   70.32 (-1.36%)
T   16.17 (-0.86%)
F   12.23 (-3.01%)
MU   121.27 (-1.02%)
GE   153.36 (-0.82%)
CGC   6.89 (-11.67%)
DIS   113.06 (-0.83%)
AMC   2.51 (-5.28%)
PFE   25.85 (-0.04%)
PYPL   63.42 (-1.81%)
XOM   119.83 (-0.45%)
NASDAQ:MNTA

Momenta Pharmaceuticals (MNTA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$52.48
$52.48
50-Day Range
$52.26
$52.49
52-Week Range
$12.21
$52.53
Volume
N/A
Average Volume
1.94 million shs
Market Capitalization
$6.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MNTA stock logo

About Momenta Pharmaceuticals Stock (NASDAQ:MNTA)

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

MNTA Stock News Headlines

Genoptix, Momenta Shares Headed for Gains
2024 Oil Boom
Wall Street’s betting on new oil bull market… JP Morgan analysts have pegged the future price of oil at $380 per barrel. That would send oil companies skyrocketing.
Eastman Kodak, Rambus: After-Hours Trading
See More Headlines
Receive MNTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Momenta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/10/2020
Today
4/15/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MNTA
CUSIP
60877T10
Fax
N/A
Employees
131
Year Founded
N/A

Profitability

Net Income
$-290,050,000.00
Net Margins
-757.61%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$23.87 million
Book Value
$4.59 per share

Miscellaneous

Free Float
N/A
Market Cap
$6.25 billion
Optionable
Optionable
Beta
1.71
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Craig A. Wheeler (Age 59)
    Pres, CEO & Exec. Director
  • Dr. Ganesh Venkataraman Kaundinya (Age 52)
    Co-Founder & Consultant
  • Dr. Santiago Arroyo (Age 59)
    Chief Medical Officer & Sr. VP of Devel.
  • Mr. Bruce A. Leicher (Age 63)
    Consultant
  • Mr. Scott M. Storer
    Consultant

MNTA Stock Analysis - Frequently Asked Questions

How were Momenta Pharmaceuticals' earnings last quarter?

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) posted its earnings results on Monday, August, 10th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.06. The biotechnology company had revenue of $6.61 million for the quarter, compared to analysts' expectations of $5.84 million. Momenta Pharmaceuticals had a negative trailing twelve-month return on equity of 61.44% and a negative net margin of 757.61%.

What other stocks do shareholders of Momenta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Momenta Pharmaceuticals investors own include Exelixis (EXEL), Novavax (NVAX), Gilead Sciences (GILD), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Pfizer (PFE), ACADIA Pharmaceuticals (ACAD), ImmunoGen (IMGN) and CRISPR Therapeutics (CRSP).

This page (NASDAQ:MNTA) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners